A randomized, double‐blinded, vehicle‐controlled clinical trial of topical cryosim‐1, a synthetic TRPM8 agonist, in prurigo nodularis
Journal of Cosmetic Dermatology · 2024-03 · 23 (3) · 931-937
DOI: 10.1111/jocd.16079 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 02.01.2024. Verfasst von Myoung Eun Choi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Prurigo, TRPM Cation Channels. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Asan Institute for Life Sciences, Asan Medical Center, Dong Wha Pharmaceutical and the National Research Foundation of Korea.
Abstract (Originalsprache)
Background
Prurigo nodularis (PN) is an intensively pruritic skin disease that negatively influences quality of life. Cryosim‐1 (Intrinsic IB Spot) is a synthetic, selective transient receptor potential melastatin 8 agonist.
Aims
To investigate the efficacy and safety of cryosim‐1 in PN patients. Patients/Methods A randomized, double‐blinded, placebo‐controlled clinical trial including 30 patients was conducted. The numerical rating scale (NRS) of pruritus was evaluated before and 2 h after cryosim‐1 application at every visit.
Results
At week 8, the mean pruritus NRS before serum application (4.7 ± 0.4 treatment, 6.1 ± 0.5 placebo; p = 0.045) and 2 h after serum application (2.8 ± 0.4 treatment, 4.3 ± 0.5 placebo; p = 0.031) were significantly lower in the treatment group, and the mean NRS for sleep disorder was significantly lower in the treatment group (2.2 ± 0.5 treatment, 4.2 ± 0.8 placebo; p = 0.031). The mean satisfaction scales for pruritus improvement were significantly higher in the treatment group (7.2 ± 0.6) than in the placebo group (4.0 ± 0.9; p = 0.005). There was no difference in TEWL between the two groups, and no adverse reactions were reported.
Conclusions
Cryosim‐1 is a safe and effective topical treatment for PN patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Bio-Medical Institute of Technology (BMIT), University of Ulsan, College of Medicine, Ulsan, Korea.
ORCID-Profile: Myoung Eun Choi
Förderung
- Asan Institute for Life Sciences, Asan Medical Center
- Dong Wha Pharmaceutical and the National Research Foundation of Korea
Zitieren
APA
Choi, M. E., Lee, J. H., Jung, C. J., Lee, W. J., Won, C. H., Lee, M. W., & Chang, S. E. (2024). A randomized, double‐blinded, vehicle‐controlled clinical trial of topical cryosim‐1, a synthetic TRPM8 agonist, in prurigo nodularis. Journal of Cosmetic Dermatology, 23(3), 931-937. https://doi.org/10.1111/jocd.16079
Vancouver
Choi ME, Lee JH, Jung CJ, Lee WJ, Won CH, Lee MW, et al. A randomized, double‐blinded, vehicle‐controlled clinical trial of topical cryosim‐1, a synthetic TRPM8 agonist, in prurigo nodularis. Journal of Cosmetic Dermatology. 2024;23(3):931-937. doi:10.1111/jocd.16079
BibTeX
@article{Choi2024,
author = {Choi, Myoung Eun and Lee, Jeong Hyeon and Jung, Chang Jin and Lee, Woo Jin and Won, Chong Hyun and Lee, Mi Woo and Chang, Sung Eun},
title = {A randomized, double‐blinded, vehicle‐controlled clinical trial of topical cryosim‐1, a synthetic TRPM8 agonist, in prurigo nodularis},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
volume = {23},
number = {3},
pages = {931--937},
doi = {10.1111/jocd.16079}
}
EUVIMED